Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Crunch Time For Aerie At EMA

An EU Marketing Recommendation Could Be In Store For New Glaucoma Treatment

Executive Summary

Aerie is already exploring its pricing strategy for Roclanda as the European Medicines Agency this week decides whether the intraocular pressure treatment should be approved in Europe.

You may also be interested in...



Phesgo & Roclanda Among New Winners At EMA

The European Medicines Agency this week recommended that five new products be granted EU marketing approval.

Boehringer & BridgeBio Seek EU Fast-Track Status; Enfortumab Vedotin Reverts To Standard Review

Applications for the accelerated assessment of planned EU marketing applications for two drugs are being considered by the European Medicines Agency.

Ophthalmic Bevacizumab Sponsor Braces For High-Stakes EMA Meeting

The sponsor of an ophthalmic formulation of bevacizumab is set to speak up for its marketing authorization application during a European Medicines Agency oral explanation meeting.

Topics

Related Companies

UsernamePublicRestriction

Register

PS143263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel